The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The pharmacology and therapeutic applications of monoclonal antibodies
Open accessAbstract
Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 new mAbs were approved by the FDA, representing 20% of the total number of approved drugs. The majority of mAb therapeutics are for oncological and immunological/infectious diseases, but these are expanding into other disease areas. Over 100 monoclonal antibodies are in development, and their unique features ensure that these will remain a part of the therapeutic pipeline. Thus, the therapeutic value and the elucidation of their pharmacological properties supporting clinical development of these large molecules are unquestioned. However, their utilization as pharmacological tools in academic laboratories has lagged behind their small molecule counterparts. Early therapeutic mAbs targeted soluble cytokines, but now that mAbs also target membrane‐bound receptors and have increased circulating half‐life, their pharmacology is more complex. The principles of pharmacology have enabled the development of high affinity, potent and selective small molecule therapeutics with reduced off‐target effects and drug‐drug interactions. This review will discuss how the same basic principles can be applied to mAbs, with some important differences. Monoclonal antibodies have several benefits, such as fewer off‐target adverse effects, fewer drug‐drug interactions, higher specificity, and potentially increased efficacy through targeted therapy. Modifications to decrease the immunogenicity and increase the efficacy are described, with examples of optimizing their pharmacokinetic properties and enabling oral bioavailability. Increased awareness of these advances may help to increase their use in exploratory research and further understand and characterize their pharmacological properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion
Köhler, G., & Milstein, C. (1976) · European Journal of Immunology · doi:10.1002/eji.1830060713 · Cited by 1,922
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Therapeutic monoclonal antibodies
Breedveld, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)01034-5 · Cited by 359
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells
ISRAEL, E. J., TAYLOR, S., WU, Z., MIZOGUCHI, E., BLUMBERG, R. S., BHAN, A., & SIMISTER, N. E. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00326.x · Cited by 329
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Davies, M. J., Gagliardino, J. J., Gray, L. J., Khunti, K., Mohan, V., & Hughes, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12128 · Cited by 294
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
Receptor-mediated transport of IgG.
Rodewald, R., & Kraehenbuhl, J. P. (1984) · The Journal of cell biology · doi:10.1083/jcb.99.1.159s · Cited by 281
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Davis, T. A., Czerwinski, D. K., & Levy, R. (1999) · PubMed · Cited by 267
Anti-CD20 monoclonal antibodies: historical and future perspectives
Lim, S. H., Beers, S. A., French, R. R., Johnson, P. W. M., Glennie, M. J., & Cragg, M. S. (2010) · Haematologica · doi:10.3324/haematol.2008.001628 · Cited by 244
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00014-x · Cited by 212
He, Y.-L., Murby, S., Warhurst, G., Gifford, L., Walker, D., Ayrton, J., Eastmond, R., & Rowland, M. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970120d · Cited by 176
Advances in antibody–drug conjugates: A new era of targeted cancer therapy
Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K., & Iyer, A. K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.011 · Cited by 174
Dahan, R., Barnhart, B. C., Li, F., Yamniuk, A. P., Korman, A. J., & Ravetch, J. V. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.001 · Cited by 165
Fully human therapeutic monoclonal antibodies.
Weiner, L. M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192105.24583.83 · Cited by 164
Pardridge, W. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.952627 · Cited by 152
Lorenzetti, R., Zullo, A., Ridola, L., Diamanti, A. P., Laganà, B., Gatta, L., Migliore, A., Armuzzi, A., Hassan, C., & Bruzzese, V. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.941919 · Cited by 135
Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn
Cooper, P. R., Ciambrone, G. J., Kliwinski, C. M., Maze, E., Johnson, L., Li, Q., Feng, Y., & Hornby, P. J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.08.035 · Cited by 127
Self-citationTherapeutic antibodies for infectious diseases
Sparrow, E. G., Friede, M., Sheikh, M., & Torvaldsen, S. (2017) · Bulletin of the World Health Organization · doi:10.2471/blt.16.178061 · Cited by 127
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection
Beccari, M. V., Mogle, B. T., Sidman, E. F., Mastro, K. A., Asiago‐Reddy, E., & Kufel, W. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00110-19 · Cited by 105
IgG2m4, an engineered antibody isotype with reduced Fc function
An, Z., Forrest, G., Moore, R., Cukan, M. C., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lü, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 104
Monoclonal Antibodies for the Treatment of Cancer
Pento, J. T. (2017) · Anticancer Research · doi:10.21873/anticanres.12040 · Cited by 104
Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy
Zhao, A., Tohidkia, M. R., Siegel, D. L., et al. (2014) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2014.958978 · Cited by 103
Martin, M. G., Wu, S. V., & Walsh, J. H. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018853506830 · Cited by 99
The transmission of immune globulins from the mother to the foetal and newborn young
Brambell, F. W. R. (1969) · Proceedings of The Nutrition Society · doi:10.1079/pns19690007 · Cited by 97
Yin, L., Chen, X., Vicini, P., Rup, B. J., & Hickling, T. P. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.03.002 · Cited by 91
Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis
Hornby, P. J., Cooper, P. R., Kliwinski, C., Ragwan, E., Mabus, J. R., Harman, B., Thompson, S., Kauffman, A. L., Yan, Z., Tam, S. H., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1212-3 · Cited by 78
Self-citationChimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety
Baldo, B. A. (2015) · Drug Safety · doi:10.1007/s40264-015-0285-9 · Cited by 74
From therapeutic antibodies to immune complex vaccines
Wang, X., Wang, B., & Wen, Y. (2019) · npj Vaccines · doi:10.1038/s41541-018-0095-z · Cited by 67
Newer agents in antiplatelet therapy: a review
Holinstat, M. A., & Yeung, J. (2012) · Journal of Blood Medicine · doi:10.2147/jbm.s25421 · Cited by 57
Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration
Hanzatian, D. K., Schwartz, A. J., Gizatullin, F., Erickson, J., Deng, K., Villanueva, R., Stedman, C., Harris, C., Ghayur, T., & Goodearl, A. D. J. (2018) · mAbs · doi:10.1080/19420862.2018.1465159 · Cited by 55
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Flego, M., Ascione, A., Cianfriglia, M., & Vella, S. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-4 · Cited by 53
Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E., & Brezski, R. J. (2015) · mAbs · doi:10.1080/19420862.2015.1022692 · Cited by 50
Recent advances in the generation of human monoclonal antibody
Yamashita, M., Katakura, Y., & Shirahata, S. (2007) · Cytotechnology · doi:10.1007/s10616-007-9072-5 · Cited by 44
Research and development of therapeutic mAbs: An analysis based on pipeline projects
Geng, X., Kong, X., Hu, H., Chen, J., Yang, F. Q., Liang, H., Chen, X., & Yuanjia, H. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1074362 · Cited by 41
Ipilimumab (Yervoy) and the TGN1412 catastrophe
Bakács, T., Mehrishi, J. N., & Moss, R. W. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.005 · Cited by 41
Therapeutic Monoclonal Antibodies in Oncology
Levene, A., Singh, G., & Palmieri, C. (2005) · Journal of the Royal Society of Medicine · doi:10.1177/014107680509800403 · Cited by 39
The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases
Bruno, V., Battaglia, G., & Nicoletti, F. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0382-6 · Cited by 35
Basic Considerations for the Use of Monoclonal Antibodies in Migraine
Levin, M., Silberstein, S. D., Gilbert, R., Lucas, S. M., Munsie, L. M., Garrelts, A., Kennedy, K. J., Everman, N., & Pearlman, E. M. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13439 · Cited by 35
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
Kang, J. C., Poovassery, J. S., Bansal, P., You, S., Manjarrés, I. M., Ober, R. J., & Ward, E. S. (2013) · mAbs · doi:10.4161/mabs.27658 · Cited by 32
Kliwinski, C. M., Cooper, P. R., Perkinson, R. A., Mabus, J. R., Tam, S. H., Wilkinson, T. M., Giles-Komar, J. M., Scallon, B. J., Powers, G. D., & Hornby, P. J. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00340.2012 · Cited by 29
Self-citationChen, X., Jiang, X., Doddareddy, R., Geist, B. J., McIntosh, T. S., Jusko, W. J., Zhou, H., & Wang, W. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244855 · Cited by 28
Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance
Wang, W., Soriano, B., & Chen, Q. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2017.09.014 · Cited by 22
Cooper, P. R., Kliwinski, C. M., Perkinson, R. A., Ragwan, E., Mabus, J. R., Powers, G. D., Dorai, H., Giles-Komar, J. M., & Hornby, P. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00225 · Cited by 16
Self-citationUnique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
Hinke, S. A., Cieniewicz, A. M., Kirchner, T., D’Aquino, K. E., Nanjunda, R. K., Aligo, J. A., Perkinson, R. A., Cooper, P. R., Boayke, K., Chiu, M. L., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.01.014 · Cited by 16
Muzammil, S., Mabus, J. R., Cooper, P. R., Brezski, R. J., Bement, C. B., Perkinson, R. A., Huebert, N. D., Thompson, S. E., Levine, D., Kliwinski, C. M., et al. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.218 · Cited by 12
Self-citation
Cited by
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Chai-1: Decoding the molecular interactions of life
Discovery, C., Boitreaud, J., Dent, J., McPartlon, M., Meier, J., Reis, V., Rogozhnikov, A., & Wu, K. (2024) · doi:10.1101/2024.10.10.615955 · Cited by 517
Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer
Marković, I., & Savvides, S. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01557 · Cited by 86
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Accelerating space radiation countermeasure development through drug repurposing
Madrid, P. B., & Chang, P. Y. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.07.002 · Cited by 6
Metadata
- Authors
- Castelli, M. S., McGonigle, P., & Hornby, P. J.
- Venue
- Pharmacology Research & Perspectives
- Publisher
- Wiley
- Published
- 2019-12
- Volume
- 7
- Issue
- 6
- Pages
- e00535-e00535
- ISSN
- 2052-1707 (ISSN-L)
- OpenAlex
- W2995755986
- Cited by
- 364
- References
- 60
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.